Although some data have raised a potential association of very low LDL-C levels and risk of hemorrhagic stroke,7,8 the decrease in ischemic stroke outweighed the potential increase in hemorrhagic stroke.4,9 The advent of inhibitors of PCSK9 (proprotein convertase subtilisin−kexin type 9) provided an opportunity to lower LDL-C to levels not previously achievable in most patients with statins and/or ezetimibe. This evidence concerns the gene PCSK9 and hemorrhagic stroke.